Charis 1000(Charis 1000) - 药物靶点：TGF-β1_在研适应症：乳腺癌_专利_临床

概要

基本信息

药物类型

合成多肽

别名

C 1K、CHARIS1000

靶点

TGF-β1

作用机制

TGF-β1抑制剂(转化生长因子β1抑制剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症

乳腺癌

非在研适应症-

原研机构

Ensol Biosciences, Inc.

在研机构

Ensol Biosciences, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Charis 1000 相关的临床试验

NCT05701644 / Completed临床1期

A Dose-block Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, First-in-human, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

A dose-block randomized, double-blind, placebo-controlled, single and multiple ascending dose, first-in-human, phase 1 first in human clinical trial to evaluate the safety, tolerability, and pharmacokinetics after subcutaneous administration of C1K in healthy Korean subjects.

开始日期2023-01-02

申办/合作机构

Ensol Biosciences, Inc.

NCT05980065 / Completed临床1期IIT

A Dose-block Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, First-in-human, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

A dose-block randomized, double-blind, placebo-controlled, single and multiple ascending dose, first-in-human, phase 1 first in human clinical trial to evaluate the safety, tolerability, and pharmacokinetics after subcutaneous administration of C1K in healthy Korean subjects.

开始日期2022-12-20

申办/合作机构